Key Highlights

  • Loss per share was USD 0.21 against an estimate of a USD 0.09 loss.
  • Loss from operations was USD 1.98 million for the quarter.
  • Cash and cash equivalents were USD 10.36 million at September 30.
  • The filing states substantial doubt about the ability to continue as a going concern.

Turn Therapeutics (NASDAQ:TTRX) reported a third quarter 2026 loss per share of USD 0.21, against an estimate of a USD 0.09 loss and a USD 0.07 loss in the third quarter of 2025. The company filed its results in its Quarterly Report for the period ended September 30, 2026.

Loss from operations was USD 1.98 million, compared with USD 1.91 million in the prior-year quarter. The quarter also included a net loss of USD 3.34 million from the change in Fair Value of a derivative Liability instrument, with no comparable amount a year earlier.

Operating Expenses

Total operating expenses were USD 1.98 million, against USD 1.91 million a year earlier. General and administrative expenses were USD 1.38 million, compared with USD 1.75 million, while Research and Development expenses were USD 605,197, compared with USD 158,699.

For the nine months ended September 30, 2026, total operating expenses were USD 4.83 million, against USD 3.67 million. Research and development expenses for the nine months were USD 1.19 million, compared with USD 230,636, and general and administrative expenses were USD 3.64 million, against USD 3.43 million.

Basic and diluted net loss per common share was USD 0.21 for the quarter, compared with USD 0.07 in the third quarter of 2025. For the nine months, the loss per share was USD 0.44, against USD 0.13.

The nine-month net loss from the change in fair value of the derivative liability instrument was USD 5.99 million, with no comparable amount in the earlier period. The company noted a 2-for-1 forward Stock Split approved by its board in September 2025.

Liquidity and Going Concern

Cash and cash equivalents were USD 10.36 million as of September 30, 2026, compared with USD 5.08 million at the prior Balance Sheet date. The filing states that, based on its current operating plan, the company estimates its cash is sufficient to fund operating and research and development expenses for its GX-03 programs in atopic dermatitis and hidradenitis suppurativa for a period described in the filing.

The filing also states that its Capital resources may not be sufficient to fund operations through at least the next 12 months from the date the financial statements were issued, which raises substantial doubt about its ability to continue as a going concern.

Direct Listing and Clinical Programs

The company completed a direct listing of its common stock on The Nasdaq Global Market on October 8, 2025. Its filing describes ongoing clinical programs for GX-03 in atopic dermatitis and hidradenitis suppurativa.

In evaluating the adequacy of accrued liabilities, the filing says the company analyzes the progress of its clinical trial, including levels of subject enrollment, invoices received and contracted costs.

Turn Therapeutics Q3 2026 Earnings: Key Takeaways

Turn Therapeutics reported a third quarter 2026 loss per share of USD 0.21 and a loss from operations of USD 1.98 million. Cash and cash equivalents were USD 10.36 million, and the filing includes a Going Concern disclosure.